beclabuvir
Beclabuvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection that has been studied in clinical trials. In February 2017, Bristol-Myers Squibb began sponsoring a post-marketing trial of beclabuvir, in combination with asunaprevir and daclatasvir, to study the combination's safety profile with regard to liver function. From February 2014 to November 2016, a phase II clinical trial was conducted on the combination of asunaprevir/daclatasvir/beclabuvir on patients infected with both HIV and HCV. Furthermore, a recent meta-analysis of six published six clinical trials showed high response rates in HCV genotype 1-infected patients treated with daclatasvir, asunaprevir, and beclabuvir irrespective of ribavirin use, prior interferon-based therapy, or restriction on noncirrhotic patients, IL28B genotype, or baseline resistance-associated variants — Wikipedia
Clinical trial activity
23 trials · 10 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2008 (NCT00664625)
Timeline
Indications
Approved for
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
- RNA-directed RNA polymeraseNEGATIVE ALLOSTERIC MODULATOR
RNA-directed RNA polymerase negative allosteric modulator
Thumb I site
- Hepatitis C virus NS5B RNA-dependent RNA polymeraseNEGATIVE ALLOSTERIC MODULATOR
Hepatitis C virus NS5B RNA-dependent RNA polymerase negative allosteric modulator
Thumb I site
Chemistry & pharmacology
SMILES
COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21- Mol. weight
- 659.85 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBeclabuvir ↗
- ChEMBLCHEMBL4105584 ↗
- ChEMBLCHEMBL3126842 ↗
Also known as
- 8-cyclohexyl-n-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide
- beclabuvir
- beclabuvir
- beclabuvir
- beclabuvir
- beclabuvir
- beclabuvir
- bms-791325
- bms-791325
- bms-791325
- bms-791325
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02292966 | Phase 4 | Jul 1, 2015 | Bristol-Myers Squibb, University of New South Wales |
| NCT02309450 | Phase 2 | Dec 1, 2014 | Bristol-Myers Squibb, French National Agency for Research on AIDS and Viral Hepatitis, Hospital Avicenne |
| NCT00947245 | Phase 1 | Oct 1, 2014 | Bristol-Myers Squibb |
| NCT02098616 | N/A | Jul 1, 2014 | Bristol-Myers Squibb, Department of Veteran Affairs, National Cancer Institute (NCI), Southern California Institute for Research and Education |
| NCT02175966 | Phase 2 | Jul 1, 2014 | Bristol-Myers Squibb |
| NCT02175602 | Phase 1 | Jun 1, 2014 | Bristol-Myers Squibb, PPD |
| NCT02170727 | Phase 3 | Jun 1, 2014 | Bristol-Myers Squibb |
| NCT02123654 | Phase 3 | Apr 1, 2014 | Bristol-Myers Squibb |
| NCT02104843 | Phase 1 | Apr 1, 2014 | Bristol-Myers Squibb |
| NCT02108639 | Phase 1 | Apr 1, 2014 | Bristol-Myers Squibb |
| NCT02112110 | Phase 1 | Apr 1, 2014 | Bristol-Myers Squibb |
| NCT02084953 | Phase 1 | Apr 1, 2014 | Bristol-Myers Squibb |
| NCT02095860 | Phase 1 | Apr 1, 2014 | Bristol-Myers Squibb |
| NCT02103569 | Phase 1 | Apr 1, 2014 | Bristol-Myers Squibb |
| NCT02045966 | Phase 1 | Feb 1, 2014 | Bristol-Myers Squibb |
| NCT02045693 | Phase 1 | Feb 1, 2014 | Bristol-Myers Squibb |
| NCT02124044 | Phase 2 | Feb 1, 2014 | Bristol-Myers Squibb, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT01973049 | Phase 3 | Dec 1, 2013 | Bristol-Myers Squibb |
| NCT01979939 | Phase 3 | Dec 1, 2013 | Bristol-Myers Squibb |
| NCT00996879 | Phase 1 | May 1, 2013 | Bristol-Myers Squibb |
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 23 | 19 | 5 | 2008 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2014 |
| French National Agency for Research on AIDS and Viral Hepatitis | Government | 1 | 1 | 1 | 2014 |
| Hospital Avicenne | Academic/Hospital | 1 | 0 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2014 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2014 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2014 |
| PPD | For profit | 1 | 0 | 1 | 2014 |
| Southern California Institute for Research and Education | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of New South Wales | Academic/Hospital | 1 | 1 | 1 | 2015 |